The Clinical Standard for Muscle Protection during GLP-1 Therapy
The clinical standard for muscle preservation during GLP-1 therapy. Physician-designed protocols that generate a Sarcopenia Risk Index (SRI) and deliver actionable protection targets.
New to MyoGuard? Create your free account →
Clinician? Register your practice →Trusted by clinicians
A global clinical response to the GLP-1 muscle loss crisis
Grounded in NEJM, EWGSOP2, and 2026 clinical literature
GDPR and HIPAA-aligned data handling
Preliminary Sarcopenia Risk Index (SRI)
No account required · Clinical parameters · Results in seconds
Body metrics
GLP-1 therapy
Symptoms & lifestyle
Recovery environment
Typical adult range: 5–9 hours
Sleep duration is displayed as a recovery context indicator. Nocturnal GH and IGF-1 secretion support muscle protein synthesis — adequate sleep optimises your protocol outcomes. This parameter is not incorporated into the sarcopenia risk score.
MyoGuard Clinical Oversight · For educational use only · Not a substitute for clinical consultation
Built on peer-reviewed evidence